Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $65
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $65.
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $65.